19313-85-0 Usage
General Description
4-(propionylamino)benzoic acid is a chemical compound with the molecular formula C11H11NO3. It is a derivative of benzoic acid with a propionylamino group attached to the fourth carbon of the benzene ring. 4-(propionylamino)benzoic acid is commonly used in pharmaceutical and medical research as a building block in the synthesis of various drugs and compounds. It has also been studied for its potential therapeutic applications in the treatment of inflammatory conditions and cancer. The chemical properties and biological activities of 4-(propionylamino)benzoic acid make it a valuable compound for further research and development in the field of medicine and pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 19313-85-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,3,1 and 3 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 19313-85:
(7*1)+(6*9)+(5*3)+(4*1)+(3*3)+(2*8)+(1*5)=110
110 % 10 = 0
So 19313-85-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H11NO3/c1-2-9(12)11-8-5-3-7(4-6-8)10(13)14/h3-6H,2H2,1H3,(H,11,12)(H,13,14)
19313-85-0Relevant articles and documents
INHIBITORS OF CYCLIN-DEPENDENT KINASES
-
Paragraph 00247, (2020/01/24)
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents
Qiu, Jingying,Xu, Bixue,Huang, Zhengming,Pan, Weidong,Cao, Peixue,Liu, Changxiao,Hao, Xiaojiang,Song, Baoan,Liang, Guangyi
experimental part, p. 5352 - 5360 (2011/10/12)
A series of Matijing-Su (MTS, N-(N-benzoyl-l-phenylalanyl)-O-acetyl-l- phenylalanol) derivatives were synthesized and evaluated for their anti-hepatitis B virus (HBV) activity in 2.2.15 cells. The IC50 of compounds 14a (0.71 μM), 13c (2.85 μM), 13b (4.37 μM), etc. and the selective index of 13g (161.01), 13c (90.45), 13a (85.09) etc. of the inhibition on the replication of HBV DNA were better than those of the positive control lamivudine (IC50: 82.42 μM, SI: 41.59). Compounds 13o, 13p, and 16a also exhibited significant anti-HBV activity.